Loading
Sinorda is a Chinese drug company, already selling a stomach-acid medicine, that is testing a cell therapy made from a patient's own T cells taken from the lymph nodes nearest the tumour.
Guizhou Sinorda Pharmaceutical Co., Ltd. (生诺医药), in the Guiyang national high-tech zone, was founded in 2010 according to the company and is a commercial-stage company focused on digestive disease, tumour immunology and autoimmune disease; its acid-related disease drug linaprazan glurate (X842) is approved in China. In oncology, its Lymph-T Exp platform expands tumour-reactive T cells from sentinel lymph nodes, which the company says has investigator-initiated clinical results in several tumours. SND002 Cell Injection, an autologous T cell product, is in a phase 1 study in advanced solid tumours including colorectal and gastric cancer (NCT07903857). Its first registered cancer trial, NCT07903857, was posted on ClinicalTrials.gov in October 2026.
Shares TIL therapy, Gastric & gastro-oesophageal junction cancer.
Shares TIL therapy, Colorectal cancer.
Shares TIL therapy, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/